

Name of the Issuer:	GPT Healthcare Limited	Last updated on	15-Nov-24
---------------------	------------------------	-----------------	-----------

1 Type of Issue (PO / FPO)	IPO
----------------------------	-----

2 Issue Size (Rs. Cr)	525.14
- Fresh Issue Size (Rs. Cr)	40.00
- Offer for Sale Component (Rs. Cr)	485.14
Source: Final Post Issue Report dated March 5, 2024	

3 Grade of issue along with name of the rating agency	
Name	Not Applicable
Grade	Not Applicable

4 Subscription Level (Number of times)	6.2600*
Source: Final Post Issue Report dated March 5, 2024	
*The above figure is after technical rejections, multiple or duplicate bids and bids not banked/returned	

5 OIB Holding (as a % of outstanding capital) as disclosed to stock exchanges	
Particulars	
(i) allotment in the issue	17.20%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (February 28, 2024)	12.81%
(iii) at the end of 1st FY (March 31, 2024) ⁽¹⁾	12.81%
(iv) at the end of 2nd FY (March 31, 2025) ⁽²⁾	Not Available
(v) at the end of 3rd FY (March 31, 2026) ⁽³⁾	Not Available
*Period not completed	
⁽¹⁾ Given that the Company was listed on Feb 29, 2024, the data is presented for the period beginning on Feb 29, 2024	

6 Financials of the issuer			
(In Rs. Crore)			
Parameters	1st FY (March 31, 2024)	2nd FY (March 31, 2025)⁽¹⁾	3rd FY (March 31, 2026)⁽²⁾
Income from operations	400.15	Not Available	Not Available
Net Profit for the period	47.77	Not Available	Not Available
Paid-up equity share capital	82.06	Not Available	Not Available
Reserves excluding revaluation reserves	1,364.35	Not Available	Not Available
*Period not completed			

7 Trading Status in the scrip of the issuer	
Company's Equity Shares are listed on both the BSE Limited and NSE. The Shares have not been suspended or delisted.	
Particulars	
(i) at the end of 1st FY (March 31, 2024)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2025) ⁽¹⁾	Not Available
(iii) at the end of 3rd FY (March 31, 2026) ⁽²⁾	Not Available
*Period not completed	

8 Change in Directors of issuer from the disclosures in the offer document		
Particulars		
(i) at the end of 1st FY (March 31, 2024)	a) Mr. Dwarka Prasad Tanti b) Mr. Anurag Tanti	Re-appointment
(ii) at the end of 2nd FY (March 31, 2025) ⁽¹⁾	Not Available	Not Available
(iii) at the end of 3rd FY (March 31, 2026) ⁽²⁾	Not Available	Not Available
Source: Stock Exchange Filings		
*Period not completed		

9 Status of implementation of project/ commencement of commercial production	
(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds			
(In Rs. Crore)			
Particulars	Amount proposed to be funded from Net Proceeds	Estimated Deployment (Financial Year 2024)	Estimated Deployment (Financial Year 2025)
Repayment or prepayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company from banks and financial institutions	30.00	20.00	10.00
General Corporate Purposes	7.52	4.52	3.00
Source: Prospectus dated February 26, 2024			
(i) Actual utilization			
(In Rs. Crore)			
Particulars	As of March 31, 2024		
Repayment or prepayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company from banks and financial institutions	573.40		
General Corporate Purposes	7.52		
* Source: Stock Exchange Intimation of statement of deviation/ variation dated May 21, 2024			
(ii) Reasons for deviation, if any	Not applicable		

11 Comments of monitoring agency, if applicable ⁽¹⁾	
(a) Comments on use of funds	Not Applicable
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other observations expressed by the monitoring agency about the end use of funds	
* Monitoring Agency is not applicable since the fresh issue size is less than Rs. 100 crores	

12 Pricing Data	
Issue Price (Rs.)	186
Designated Stock Exchange:	BSE
Listing Date:	29-Feb-24

Price parameters	At close of listing day (Feb 29, 2024)	At close of 30th calendar day from listing day (Mar 29, 2024) ⁽¹⁾	At close of 90th calendar day from listing day (May 28, 2024) ⁽²⁾	As at the end of 1st FY after the listing of the issue (March 31, 2024) ⁽³⁾⁽⁴⁾			As at the end of 2nd FY after the listing of the issue (March 31, 2025) ⁽⁵⁾⁽⁶⁾			As at the end of 3rd FY after the listing of the issue (March 31, 2026) ⁽⁷⁾⁽⁸⁾		
				Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange	200.75	176.45	147.55	176.45	219.70	199.80	Not available	Not available	Not available	Not available	Not available	
BSE SENSEX	72,690.30	73,651.35	75,170.65	74,651.26	74,245.17	71,674.42	Not available	Not available	Not available	Not available	Not available	
BSE HEALTHCARE ⁽⁹⁾	35,079.32	36,052.84	35,662.18	35,052.84	35,342.21	33,389.29	Not available	Not available	Not available	Not available	Not available	

Note:

(1) 30th calendar day shall be taken as listing date plus 29 calendar days.

(2) 90th calendar day shall be taken as listing date plus 89 calendar days. Since 90th calendar day is a Saturday, the next trading day is considered.

(3) High and Low based on intra day prices.

(4) Pricing data not disclosed as the relevant fiscal year and period have not completed.

(5) BSE HEALTHCARE index represents the relevant sectoral index.

(6) Given that the Company was listed on Feb 29, 2024, the data is presented for the period beginning on Feb 29, 2024.

(7) In case of reporting date falling on a trading holiday, values for the trading day immediately preceding the trading holiday has been considered.

25 June 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation - Please find enclosed herewith intimation for investor meet on June 28, 2024.
26 June 2024	Closure of Trading Window - Please find enclosed herewith intimation for the closure of trading window w.e.f Monday, July 1, 2024 until 48 hours from the declaration of Financial Results for the Q.E. June 30, 2024.
01 July 2024	Shareholders Meeting-35Th AGM On Thursday, July 25, 2024 - Please find enclosed herewith Notice of 35th AGM of the Company.
01 July 2024	Reg. 34 (1) Annual Report - Please find enclosed herewith the Annual Report including Notice of 35th Annual General Meeting of the Company.
02 July 2024	Announcement under Regulation 30 (LODR)-Newspaper Publication - Please find enclosed herewith News Paper Publication related to 35th AGM of the Company.
04 July 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation - Please find enclosed herewith intimation for Investor Meet on Tuesday, July 09, 2024.
15 July 2024	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 - Please find enclosed herewith the certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the Quarter Ended June 30, 2024.
25 July 2024	Shareholder Meeting / Postal Ballot-Outcome of AGM - Please find the Outcome of the 35th Annual General Meeting of GPT Healthcare Limited Held on July 25, 2024.
26 July 2024	Shareholder Meeting / Postal Ballot-Scrutinizer's Report - Please find the enclosed Voting Results and Scrutinizer Report on 35th AGM of the Company.
07 August 2024	Board Meeting Intimation for To Consider And Approve The Un-Audited Financial Results Along With Report Of The Statutory Auditors Thereon Of The Company For The 1st Quarter Ended June 30, 2024 - GPT Healthcare Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024. Inter-ala to consider and approve Un-audited Financial Results along with Report of the Statutory Auditors thereon of the Company for the 1st quarter ended June 30, 2024.
07 August 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation - Please find enclosed herewith the invitation for the Earnings call for the 1st quarter ended June 30, 2024.
13 August 2024	Board Meeting Outcome for Outcome Of The Board Meeting Held On August 13, 2024
13 August 2024	Submission Of Un-Audited Financial Results For The Quarter Ended June 30, 2024
13 August 2024	Announcement under Regulation 30 (LODR)-Investor Presentation - Please find enclosed herewith the Investor Presentation for Q1 FY 2025.
13 August 2024	Announcement under Regulation 30 (LODR)-Press Release / Media Release - Please find press release on the Quarterly Results for Q1 FY 2025.
13 August 2024	Announcement under Regulation 30 (LODR)-Newspaper Publication - Please find enclosed herewith News Paper Publication of Q1 FY 2025 Financial Results.
14 August 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome - Please find the Audio Link of Investor Call on the financial performance of the Company for the 1st quarter ended June 30, 2024.
16 August 2024	Announcement under Regulation 30 (LODR)-Earnings Call Transcript - Please find enclosed herewith the transcript of the earnings call held on August 14, 2024 to discuss the Q1 FY2025 result.
22 August 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation - Please find the enclosed intimation for investor meet on August 27, 2024.
29 August 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation - Please find enclosed intimation for investor meet on September 4, 2024.
14 October 2024	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 - Please find enclosed herewith the Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for the Q.E. September 30, 2024.
04 November 2024	Board Meeting Intimation for Considering Inter Ala And Approving The Unaudited Financial Results (Standalone) Of The Company For The 2Nd Quarter And Half Year Ended On September 30, 2024 And To Declare Interim Dividend For The Financial Year 2024-25.
06 November 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation - Please find enclosed herewith the invitation for the Earnings call for the 2nd quarter and half year ended September 30, 2024.
14 November 2024	Board Meeting Outcome for Q2FY25 Results - Please find the outcome of the Board Meeting dated November 14, 2024.
14 November 2024	Results-Financial Results For 2Nd Quarter And Half Year Ended September 30, 2024 - Please find the Q2FY25 Results
14 November 2024	Corporate Action-Board approves Dividend - Please find the Intimation of Record date for the First Interim Dividend for the FY 2024-25.
14 November 2024	Announcement under Regulation 30 (LODR)-Press Release / Media Release - Please find the Press Release on the Q2FY25 results.
14 November 2024	Announcement under Regulation 30 (LODR)-Investor Presentation - Please find the Investor Presentation for Q2FY25 Results.
15 November 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome - Please find the Audio Recording of the Investor Call held on November 14, 2024.
16 November 2024	Announcement under Regulation 30 (LODR)-Newspaper Publication - Please find the News Paper Publication on Q2FY25 Results and Notice of Record Date.

Notes:
The Company meets Investors' Analysts/Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable.
For further updates and information, please refer to the website of the Stock Exchanges i.e. www.bseindia.com and/ or www.nseindia.com

Disclaimer:
The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIR/MRSD/12/2012 dated January 10, 2012.

This information is gathered, inter-ala, from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and/ or the National Stock Exchange of India Limited ("NSE") and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information/ clarifications provided by the Issuer.

Nothing in this information is intended by JM Financial to be construed as legal, regulatory, accounting, tax or other advice. While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, JM Financial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither JM Financial nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and/ or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement. JM Financial does not undertake to update the information contained herein except as required by applicable law or regulation.